BRIDGEWATER, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer of VYNE, is scheduled to participate at the H.C. Wainwright 24th Annual Global Investment Conference (Hybrid) on September 13, 2022. Management will also be available for one-on-one meetings with investors. H.C. Wainwright 24th Annual Global Investment Conference – Presentation Details Date: Tuesday, September 13, 2022 Time: 12:30 p.m. ET Format: Company Presentation Presenter: David Domzalski, President and Chief…